About valneva se - INRLF
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
INRLF At a Glance
Valneva SE
Campus Bio-Ouest
Saint-Herblain, Grand Est 44800
| Phone | 33-2-28-07-37-10 | Revenue | 197.12M | |
| Industry | Biotechnology | Net Income | -130,003,151.28 | |
| Sector | Health Technology | 2025 Sales Growth | 7.46% | |
| Fiscal Year-end | 12 / 2026 | Employees | 674 | |
| View SEC Filings |
INRLF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.726 |
| Price to Book Ratio | 6.073 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.718 |
| Enterprise Value to Sales | 4.307 |
| Total Debt to Enterprise Value | 0.287 |
INRLF Efficiency
| Revenue/Employee | 292,457.413 |
| Income Per Employee | -192,883.014 |
| Receivables Turnover | 6.034 |
| Total Asset Turnover | 0.396 |
INRLF Liquidity
| Current Ratio | 2.384 |
| Quick Ratio | 1.846 |
| Cash Ratio | 1.175 |
INRLF Profitability
| Gross Margin | 35.91 |
| Operating Margin | -53.152 |
| Pretax Margin | -68.168 |
| Net Margin | -65.953 |
| Return on Assets | -26.097 |
| Return on Equity | -83.235 |
| Return on Total Capital | -35.318 |
| Return on Invested Capital | -35.552 |
INRLF Capital Structure
| Total Debt to Total Equity | 195.208 |
| Total Debt to Total Capital | 66.126 |
| Total Debt to Total Assets | 51.963 |
| Long-Term Debt to Equity | 175.763 |
| Long-Term Debt to Total Capital | 59.539 |